Treace Medical Concepts Inc
$ 2.72
-1.09%
19 May - close price
- Market Cap 178,401,000 USD
- Current Price $ 2.72
- High / Low $ 2.99 / 2.53
- Stock P/E N/A
- Book Value 1.19
- EPS -0.96
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.67 %
- 52 Week High 7.78
- 52 Week Low 1.17
About
Treace Medical Concepts, Inc., an orthopedic medical device company, is dedicated to the design, manufacture, and marketing of biological devices and / or solutions for foot and ankle surgeons in the United States. The company is headquartered in Ponte Vedra Beach, Florida.
Analyst Target Price
$4.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-02-27 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-09 | 2023-08-08 |
| Reported EPS | -0.1154 | -0.0783 | -0.26 | -0.28 | -0.2468 | -0.0016 | -0.25 | -0.29 | -0.3 | -0.1 | -0.28 | -0.2 |
| Estimated EPS | -0.243 | -0.1521 | -0.28 | -0.29 | -0.3022 | -0.0427 | -0.27 | -0.29 | -0.3 | -0.09 | -0.26 | -0.24 |
| Surprise | 0.1276 | 0.0738 | 0.02 | 0.01 | 0.0554 | 0.0411 | 0.02 | 0 | 0 | -0.01 | -0.02 | 0.04 |
| Surprise Percentage | 52.5103% | 48.5207% | 7.1429% | 3.4483% | 18.3322% | 96.2529% | 7.4074% | 0% | 0% | -11.1111% | -7.6923% | 16.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TMCI
2026-05-20 03:39:18
This page provides a comprehensive resource for investors and traders to access official regulatory documents for Treace Medical Concepts (TMCI), including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. Recent filings detail beneficial ownership by Armistice Capital and Steven Boyd, as well as insider transactions for several company officers, including the CFO, C. Legal & Compliance Officer, Chief Innovation Officer, and SVP of Sales. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis for enhanced investor insight.
2026-05-20 00:39:18
Treace Medical Concepts (TMCI) director Lawrence W. Hamilton was granted 30,000 restricted stock units (RSUs) as compensation, not via an open-market purchase. These RSUs will vest 100% on the earlier of May 19, 2027, or the 2027 annual meeting of stockholders, provided Hamilton remains with the company. He has elected to defer receiving the underlying shares until a change in control or his separation from service, bringing his total direct holdings to 74,056 shares.
2026-05-20 00:39:18
Deepti Jain, a director at Treace Medical Concepts (TMCI), has received a grant of 30,000 restricted stock units (RSUs) at no purchase price. These RSUs will vest 100% on the earlier of May 19, 2027, or the 2027 annual stockholders' meeting, contingent on her continued service. Following this transaction, Jain's total holdings, including the RSUs, amount to 100,243 common shares.
2026-05-15 15:40:57
Armistice Capital, LLC and Steven Boyd have reported a 9.85% beneficial ownership stake in Treace Medical Concepts, Inc. (TMCI), totaling 6,364,000 shares of common stock. This disclosure was made via a Schedule 13G/A amendment, indicating that Armistice Capital, as the investment manager for Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these shares. The filing clarifies the reporting persons and their responsibilities under an Investment Management Agreement, explicitly disclaiming direct beneficial ownership for the Master Fund due to its inability to vote or dispose of the securities directly.
2026-05-15 10:40:57
This article reports on an insider purchase of Treace Medical Concepts shares. An insider recently bought shares worth $375,505, as disclosed in a recent SEC filing.
2026-05-15 07:38:00
John T. Treace, CEO of Treace Medical Concepts (NASDAQ: TMCI), recently purchased approximately $375,505 worth of the company's common stock over three days in mid-May 2026. These purchases occurred at prices between $2.1739 and $2.6153 per share, preceding a significant stock rally. The CEO now directly holds over 7.15 million shares, and the company also reported better-than-expected Q1 2026 earnings despite a revenue decline.
